Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Dynavax Technologies Corp. Investo...
December 07 2016 - 1:51PM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces that a
class action lawsuit has been filed on behalf of investors who
purchased Dynavax Technologies Corporation (“Dynavax” or the
“Company”) (NASDAQ: DVAX) securities between March 10, 2014 and
November 11, 2016, inclusive (the “Class Period”). Dynavax
investors have until January 17, 2017 to file a
lead plaintiff motion.
Investors suffering losses on their Dynavax investments are
encouraged to contact Lesley Portnoy of GPM to discuss their legal
rights in this class action at 310-201-9150 or by email to
shareholders@glancylaw.com.
According to the Complaint filed in this lawsuit, throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts
about the Company’s business, operations, and prospects.
Specifically, Defendants made false and/or misleading statements
and/or failed to disclose that: (1) there were significant adverse
events associated with Dynavax’s HEPLISAV-B product, including an
imbalance in the number of cardiac events during use; (2)
consequently, a commercial product launch of HEPLISAV-B was less
imminent than Dynavax had led investors to believe; and (3) as a
result, Dynavax’s public statements were materially false and
misleading at all relevant times.
If you purchased shares of Dynavax during the Class Period you
may move the Court no later than January 17,
2017 to ask the Court to appoint you as lead plaintiff. To
be a member of the Class you need not take any action at this time;
you may retain counsel of your choice or take no action and remain
an absent member of the Class. If you wish to learn
more about this action, or if you have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
www.glancylaw.com. If you inquire by email please include your
mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161207006111/en/
Glancy Prongay and Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224www.glancylaw.comshareholders@glancylaw.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024